For example, the binding of PD-L1 to immune checkpoint PD-1, as well as the binding of CTLA-4 to CD80/CD86 ligands, are key inhibitory checkpoint signals that limit T cell activation and block its action on tumor cells [35, 36]. Here, CD86 is linked to neoplasm.